您的购物车当前为空
别名 S7, MS4A2, MS4A-1, MS4A1, Ly-44, LEU-16, CVID5, CD20S7, CD20 receptor, CD20, Bp35, B1
B-lymphocyte antigen CD20 or CD20 is an activated-glycosylated phosphoprotein expressed on the surface of all B-cells beginning at the pro-B phase (CD45R , CD117) and progressively increasing in concentration until maturity.CD20 is the target of the monoclonal antibodies rituximab, ocrelizumab, obinutuzumab, ofatumumab, ibritumomab tiuxetan, tositumomab, and ublituximab, which are all active agents in the treatment of all B cell lymphomas, leukemias, and B cell-mediated autoimmune diseases. CD20 Protein, Human, Recombinant (His & Avi) is expressed in E. coli expression system with C-His-Avi tag. The predicted molecular weight is 16.8 kDa and the accession number is P11836-1.

B-lymphocyte antigen CD20 or CD20 is an activated-glycosylated phosphoprotein expressed on the surface of all B-cells beginning at the pro-B phase (CD45R , CD117) and progressively increasing in concentration until maturity.CD20 is the target of the monoclonal antibodies rituximab, ocrelizumab, obinutuzumab, ofatumumab, ibritumomab tiuxetan, tositumomab, and ublituximab, which are all active agents in the treatment of all B cell lymphomas, leukemias, and B cell-mediated autoimmune diseases. CD20 Protein, Human, Recombinant (His & Avi) is expressed in E. coli expression system with C-His-Avi tag. The predicted molecular weight is 16.8 kDa and the accession number is P11836-1.
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 5 μg | ¥ 343 | 现货 | |
| 10 μg | ¥ 549 | 现货 | |
| 20 μg | ¥ 898 | 现货 | |
| 50 μg | ¥ 1,760 | 现货 | |
| 100 μg | ¥ 2,960 | 现货 | |
| 200 μg | ¥ 5,350 | 3日内发货 | |
| 500 μg | ¥ 11,800 | 现货 |
| 产品描述 | B-lymphocyte antigen CD20 or CD20 is an activated-glycosylated phosphoprotein expressed on the surface of all B-cells beginning at the pro-B phase (CD45R , CD117) and progressively increasing in concentration until maturity.CD20 is the target of the monoclonal antibodies rituximab, ocrelizumab, obinutuzumab, ofatumumab, ibritumomab tiuxetan, tositumomab, and ublituximab, which are all active agents in the treatment of all B cell lymphomas, leukemias, and B cell-mediated autoimmune diseases. CD20 Protein, Human, Recombinant (His & Avi) is expressed in E. coli expression system with C-His-Avi tag. The predicted molecular weight is 16.8 kDa and the accession number is P11836-1. |
| 生物活性 | Immobilized Human CD20, His Tag at 2μg/ml (100μl/well) on the plate. Dose response curve for Anti-CD20 Antibody, hFc Tag with the EC50 of 0.33μg/ml determined by ELISA. |
| 研究背景 | B-lymphocyte antigen CD20 or CD20 is an activated-glycosylated phosphoprotein expressed on the surface of all B-cells beginning at the pro-B phase (CD45R , CD117) and progressively increasing in concentration until maturity.CD20 is the target of the monoclonal antibodies rituximab, ocrelizumab, obinutuzumab, ofatumumab, ibritumomab tiuxetan, tositumomab, and ublituximab, which are all active agents in the treatment of all B cell lymphomas, leukemias, and B cell-mediated autoimmune diseases. |
| 种属 | Human |
| 表达系统 | E. coli |
| 标签 | C-His-Avi |
| 蛋白编号 | P11836-1 |
| 蛋白构建 | Ile141-Ser188 |
| 蛋白纯度 | > 95% as determined by Tris-Bis PAGE |
| 蛋白性状 | Solution |
| 缓冲液 | Supplied as 0.22 μm filtered solution in 20 mM PB, 10% Glycerol, 0.4M Urea, 1 mM GSH, 0.1 mM GSSG (pH 7.0). |
| 别名 | S7, MS4A2, MS4A-1, MS4A1, Ly-44, LEU-16, CVID5, CD20S7, CD20 receptor, CD20, Bp35, B1 |
| 内毒素 | < 1 EU/μg by the LAL method. |
| 分子量 | 16.8 kDa (predicted) same as Tris-Bis PAGE result. |
| 颜色 | Transparent |
| 物理性状 | Solution |
| 运输方式 | In general, Lyophilized powders are shipping with blue ice. Solutions are shipping with dry ice. |
| 存储 | It is recommended to store the product under sterile conditions at -70°C or lower. Samples are stable for up to 12 months at -80°C. Please avoid multiple freeze-thaw cycles and store products in aliquots. |
对于不同动物的给药剂量换算,您也可以参考 更多